XML 32 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statement of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities    
Net loss $ (36,080) $ (24,278)
Adjustments to reconcile net loss to net cash used in operating activities    
Stock-based compensation expense 4,288 1,379
Depreciation 296 312
Amortization of debt discount and issuance costs 267 3,492
Non-cash interest expense 806 3,447
PIK interest paid on repayment of term loan 0 (4,081)
Inventory write-downs 242 320
Realized loss from sale of short-term investments 0 15
Change in fair value of redeemable convertible preferred stock warrant liability 5,236 (181)
Change in fair value of derivative instrument 0 (149)
Loss on extinguishment of convertible notes 0 182
Changes in operating assets and liabilities    
Accounts receivable 1,304 (2,378)
Inventory (1,156) 672
Prepaid expenses and other assets (1,164) 120
Accounts payable 479 (5)
Accrued liabilities 1,719 (712)
Other liabilities (248) 248
Deferred rent (566) (12)
Net cash used in operating activities (24,577) (21,609)
Cash flows from investing activities    
Acquisition of property and equipment (384) (62)
Proceeds from sale of short-term investments 0 6,300
Purchase of short-term investments (85,012) (17,005)
Net cash used in investing activities (85,396) (10,767)
Cash flows from financing activities    
Proceeds from issuance of common stock under employee plans 919 11
Proceeds from issuance of common stock in initial public offering, net of underwriter discount and commissions 109,089 0
Payment of deferred offering costs (3,392) (210)
Proceeds from debt 0 54,047
Payment of debt issuance costs 0 (950)
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs 0 31,696
Repayment of debt (4,090) (42,120)
Issuance of convertible notes, net of issuance costs (includes $0 and $11,867 from related parties in the years 2021 and 2020, respectively) 0 12,535
Net cash provided by financing activities 102,526 55,009
Net (decrease) increase in cash and cash equivalents (7,447) 22,633
Cash, cash equivalents and restricted cash    
Beginning of year 26,756 4,123
End of year 19,309 26,756
Reconciliation of cash, cash equivalents and restricted cash to balance sheets:    
Cash and cash equivalents 19,187 26,390
Restricted cash 122 366
Total cash, cash equivalents and restricted cash 19,309 26,756
Supplemental disclosure of cash flow information:    
Cash paid for interest 6,337 4,411
Supplemental disclosures of non-cash investing and financing information:    
Net change in accrued liabilities from early exercise of options 2 2
Conversion of convertible notes and accrued interest into preferred stock 0 34,113
Extinguishment of derivative liability 0 6,239
Issuance of redeemable convertible preferred stock warrants in connection with the New Term Loan 0 550
Unpaid deferred offering costs included in accounts payable and accrued liabilities $ 0 $ 274